6 dated developments from July 2026 that bear on AI compliance, each checked against the source linked. Entries are tagged by industry; the newest developments and fixed deadlines ahead are on the AI regulation news page.
Feeds (Atom): All changes · Banks and credit unions · Private equity and asset managers · Hospitals and health systems · Insurers · Employers and HR · Law firms and legal teams · Manufacturers · Importers and exporters. Data: updates.json.
Regulation (EU) 2026/1744 moves stand-alone high-risk duties to December 2, 2027 and high-risk AI in regulated products to August 2, 2028. Prohibitions and general-purpose AI model duties are not delayed. Article 50 transparency duties apply from August 2, 2026, with a grace period to December 2, 2026 for the Article 50(2) marking duty on generative systems placed on the market before August 2, 2026. The regulation also moves the Machinery Regulation from Annex I Section A to Section B, which changes how much of the AI Act applies to AI in machinery.
Source: Regulation (EU) 2026/1744, EUR-Lex · Guide: EU AI Act compliance
Regulation (EU) 2026/1744 moves the Machinery Regulation from Annex I Section A to Section B, so only Article 6(1), Article 60a, and Articles 102 to 112 of the AI Act apply to AI systems that are high-risk under Article 6(1) as a safety component of machinery or as machinery itself. It requires Commission delegated acts adding health and safety requirements for high-risk AI systems to the Machinery Regulation, to apply by August 2, 2028.
Source: Regulation (EU) 2026/1744, EUR-Lex · Guide: EU AI Act compliance
Working group materials said company surveys would stay open through September 30, versions 5.0 and 6.0 would be exposed for comment, and version 7.0 would be presented at the Fall National Meeting for adoption consideration. It had not been adopted as of October 21, 2026.
Source: NAIC Big Data and AI (H) Working Group materials, July 22, 2026 · Guide: AI in insurance
The rule states that ECOA does not authorize disparate impact liability and deletes the effects test language from Regulation B. The adverse action reasons requirement in 12 CFR 1002.9 is unchanged.
Source: Federal Register, 91 FR 21620 · Guide: AI in financial services
The final rule moves the UAE from Country Groups D:3 and D:4 to A:5. Advanced computing items still need a license to or within the UAE unless the ultimate consignee and all end users are UAE Government entities or entities listed in supplement no. 8 to part 740 as approved to receive such items license-free, including listed US-headquartered AI companies and their UAE subsidiaries. Approval does not override part 744 end-use and end-user license requirements. The rule also restates that BIS enforces the license requirement for 3A090.a, 4A090.a, and related .z items only for D:1, D:4, and D:5 destinations (excluding those also in A:5 or A:6) and for D:5- or Macau-headquartered entities wherever located.
Source: Enhanced Favorable Treatment for the United Arab Emirates Under the EAR, 91 FR 43034 · Guide: AI compliance, layer by layer
Before a health care insurer denies a claim or a prior authorization that involves medical necessity, a medical director must individually review it, exercise independent medical judgment, and not rely solely on recommendations from any other source. The act is effective from and after June 30, 2026. The law does not mention AI.
Source: Laws 2025, Chapter 165 (HB 2175), Arizona Legislature · Guide: AI in health care